Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | IL6ST | P40189 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132736 | 1.00 | PPARA (0.47) | PPARAPPARGNAAAACEPTPN1 | |
| SCHEMBL8887105 | 0.97 | PPARA (0.46) | PPARAPPARGNAAAPTPN1IL6ST | |
| SCHEMBL8811308 | 0.97 | PPARA (0.46) | PPARAPPARGNAAAPTPN1IL6ST | |
| SCHEMBL6668331 | 0.93 | PPARA (0.44) | PPARAPPARGNAAAIL6STFAAH | |
| SCHEMBL6668336 | 0.93 | PPARA (0.44) | PPARAPPARGNAAAIL6STFAAH | |
| SCHEMBL6668597 | 0.93 | PPARA (0.44) | PPARAPPARGNAAAIL6STFAAH | |
| SCHEMBL6068528 | 0.89 | PPARA (0.43) | PPARANAAAIL6STFAAHSLC1A1 | |
| SCHEMBL6068526 | 0.89 | PPARA (0.43) | PPARANAAAIL6STFAAHSLC1A1 | |
| SCHEMBL6069116 | 0.89 | PPARA (0.43) | PPARANAAAIL6STFAAHSLC1A1 | |
| SCHEMBL13030016 | 0.89 | PPARA (0.52) | PPARAPPARGNAAAACEIL6ST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-1585518-B9 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1585518-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1585757-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1585518-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1509218-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070173542-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2007-07-26 | — | — | US | disclosed |
| EP-1585757-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1585518-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222412-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2005-10-06 | — | — | US | disclosed |
| WO-2005032550-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1509218-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | PPARA 3924/4885PPARG 4547/4885NAAA 583/4885 |
| US-20050222412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | PPARA 4010/4885PPARG 4526/4885NAAA 935/4885 |
| US-20070173542-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | PPARA 4010/4885PPARG 4526/4885NAAA 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.